Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.

Oncotarget - 1 Jul 2010

Beloueche-Babari Mounia, Arunan Vaitha, Jackson L Elizabeth, Perusinghe Nina, Sharp Swee Y, Workman Paul, Leach Martin O

Abstract excerpt

Molecular chaperone heat shock protein 90 (Hsp90) inhibitors are promising targeted cancer therapeutic drugs, with the advantage that they deplete multiple oncogenic client proteins and modulate all the classical hallmarks of cancer. They are now in clinical trial and show potential for activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to Biomarkers, Pharmacological
Share to HSP90 Heat-Shock Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lactams, Macrocyclic

Share to Magnetic Resonance Spectroscopy

Share to Naphthalenes

Share to Pyrazoles

Share to Pyrones

Source

Open in PubMed Open full text

Identifiers

PMID: 21037799
DOI: 10.18632/oncotarget.125
PMCID: PMC2965833

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21037799-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.PMID 21037799Read ↗

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.Semantic proximity Read ↗

The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.Semantic proximity Read ↗

17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.Semantic proximity Read ↗

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.Semantic proximity Read ↗

Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells.Semantic proximity Read ↗

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.Semantic proximity Read ↗

Assessment of Metabolic Imaging Biomarkers for MEK Inhibition Therapy Response in MelanomaSemantic proximity Read ↗

Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.Semantic proximity Read ↗

MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma ModelsSemantic proximity Read ↗

Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.Semantic proximity Read ↗

Metabolite Changes in BT4C Rat Gliomas Undergoing Ganciclovir-Thymidine Kinase Gene Therapy-induced Programmed Cell Death as Studied by 1H NMR Spectroscopy in Vivo, ex Vivo, and in VitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.